Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome.
An evaluation was carried out of the effect of domperidone on gastro-intestinal symptoms in patients with irritable bowel syndrome. Ninety-eight patients were included; 32 in an open pilot study and 66 in a double-blind placebo-controlled study. Domperidone was taken at a dosage of 10 mg tablets 4-times daily. At the end of the 4-week treatment, symptoms had disappeared or were at least markedly improved in about 80% of the domperidone-treated patients. Significant superiority of domperidone to the placebo was observed for the symptom clusters 'post-prandial flatulence', 'abdominal pain' and 'abnormal bowel habit'. No side-effects were reported.
D000005:Abdomen; D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003672:Defecation / Q000187:drug effects; D004294:Domperidone; D004311:Double-Blind Method; D005260:Female; D005414:Flatulence / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010865:Pilot Projects; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos
D001562:Benzimidazoles; D010880:Piperidines; D010919:Placebos; D004294:Domperidone